Drug intelligence / Profile preview

Poria acid

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Poria acid (PAC) is a triterpene compound derived from Poria cocos, a traditional Chinese medicine. It is being investigated for its therapeutic effects in renal cell carcinoma (RCC), where it has been shown to inhibit the growth and metastasis of RCC cells by targeting and inhibiting the PI3K/Akt/NF-κB signaling pathway.

Targets

NF-κBPI3K (Phosphoinositide-3-kinase regulatory subunit 6)AKT (RAC-alpha serine/threonine-protein kinase)

Beyond the preview

Go deeper on Poria acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Poria acid.

Explore the full profile